Difference between revisions of "Bavituximab (PGN-401)"
Jump to navigation
Jump to search
(Created page with "=Mechanism of action= Binds to phosphatidylserine, provoking an immune response. =Preliminary data= ==Non-small cell lung cancer== # Digumarti R, Bapsy PP, Suresh AV, Bha...") |
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
||
| Line 4: | Line 4: | ||
=Preliminary data= | =Preliminary data= | ||
==[[Non-small cell lung cancer]]== | ==[[Non-small cell lung cancer]]== | ||
| − | # Digumarti R, Bapsy PP, Suresh AV, Bhattacharyya GS, Dasappa L, Shan JS, Gerber DE. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Aug 24. [Epub ahead of print] [ | + | # Digumarti R, Bapsy PP, Suresh AV, Bhattacharyya GS, Dasappa L, Shan JS, Gerber DE. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Aug 24. [Epub ahead of print] [https://www.ncbi.nlm.nih.gov/pubmed/25236982 PubMed] |
[[Category:Drug index]] | [[Category:Drug index]] | ||
Revision as of 02:20, 2 December 2016
Mechanism of action
Binds to phosphatidylserine, provoking an immune response.
Preliminary data
Non-small cell lung cancer
- Digumarti R, Bapsy PP, Suresh AV, Bhattacharyya GS, Dasappa L, Shan JS, Gerber DE. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Aug 24. [Epub ahead of print] PubMed